BYLieve study results: Alpelisib and endocrine therapy in patients with PIK3CA-mutated/HR /HER2- advanced breast cancer

Advances in PARP inhibitor use for metastatic breast cancer

The future of PARP inhibitors in metastatic breast cancer

A phase II study of bemcentinib with pembrolizumab in patients with advanced NSCLC

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer

Managing metastatic breast cancer and beyond using PARP inhibitors

Updates in metastatic and early-stage breast cancer

PARP inhibitors in metastatic breast cancer: Where are we now?

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies

VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients

Genetic testing and PARP inhibitors in metastatic prostate cancer

Breast cancer highlights from ASCO 2019